Texas MPN Workshop 2022 | Updates on the use of momelotinib for the treatment of MF & clinical trials evaluating this agent
In this video, Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, shares some recent updates on the use of momelotinib for the treatment of myelofibrosis (MF) and clinical trials evaluating this agent. Dr Mesa also highlights the potential FDA approval of this agent in 2023, and shares his thoughts on the future role of momelotinib in the MF treatment landscape. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.
Disclosures
Research funding: Genentech, Promedior, Samus, Gilead, Celgene, Novartis, Constellation Pharmaceuticals, CTI, Abbvie, Sierra Oncology, Incyte Corproation; Consultancy: Novartis, Sierra Oncology, Pharma, Constellation Pharmaceuticals, AOP, La Jolla Pharma, Incyte Corporation.
